# Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard Antibiotics

> **NCT00136292** · PHASE1 · COMPLETED · sponsor: **Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 33 (actual)

## Conditions studied

- Gram-positive Bacterial Infections

## Interventions

- **DRUG:** daptomycin

## Key facts

- **NCT ID:** NCT00136292
- **Lead sponsor:** Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08-24
- **Primary completion:** 2006-08-01
- **Final completion:** 2006-08-09
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2020-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00136292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00136292, "Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard Antibiotics". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00136292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*